Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Monday, November 10, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced a $75 million offering of common stock, pre-funded warrants, and warrants. This funding aims to support the company's operations and advance its gene editing therapies developed through its ARCUS® platform. The company is targeting high unmet need diseases, indicating a strong focus on innovation in the biopharma sector.
Price reaction · baseline $6.07 (2025-11-10 close) · hit after-hours · clean, no other DTIL news in the window
day 0 close
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is raising $75 million to support its operations.
  • The company is focused on developing innovative gene editing therapies.
  • The funding will help advance its proprietary ARCUS® platform.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 10, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed

Frequently Asked Questions

What is the amount of funding Precision BioSciences announced?

Precision BioSciences announced a $75 million offering.

What platform does Precision BioSciences use for gene editing?

The company utilizes its proprietary ARCUS® platform.

What is the focus of Precision BioSciences' therapies?

The therapies target high unmet need diseases.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform biopharma
Last updated: Nov 10, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →